KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $5.2 billion.

  • Eli Lilly's Other Accumulated Expenses fell 653.91% to $5.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 billion, marking a year-over-year decrease of 653.91%. This contributed to the annual value of $5.3 billion for FY2024, which is 6095.15% up from last year.
  • As of Q3 2025, Eli Lilly's Other Accumulated Expenses stood at $5.2 billion, which was down 653.91% from $5.1 billion recorded in Q2 2025.
  • In the past 5 years, Eli Lilly's Other Accumulated Expenses ranged from a high of $5.6 billion in Q3 2024 and a low of $2.0 billion during Q3 2022
  • Its 5-year average for Other Accumulated Expenses is $3.4 billion, with a median of $2.8 billion in 2022.
  • In the last 5 years, Eli Lilly's Other Accumulated Expenses plummeted by 2367.33% in 2022 and then skyrocketed by 11583.89% in 2024.
  • Over the past 5 years, Eli Lilly's Other Accumulated Expenses (Quarter) stood at $3.0 billion in 2021, then fell by 6.01% to $2.8 billion in 2022, then grew by 15.32% to $3.3 billion in 2023, then soared by 60.95% to $5.3 billion in 2024, then fell by 1.25% to $5.2 billion in 2025.
  • Its Other Accumulated Expenses stands at $5.2 billion for Q3 2025, versus $5.1 billion for Q2 2025 and $3.8 billion for Q1 2025.